Reviewer's report
Title:Phase I Study of Miriplatin combined with Transarterial Chemotherapy
using CDDP powder in Patients with Hepatocellular Carcinoma
Version: 1Date:17 June 2012
Reviewer: Arndt Vogel
Reviewer's report:
Kamimura performed a phase 1 study to determine the maximum tolerated dose
and dose-limiting toxicity for the combination of transarterial oily
chemoembolization and transarterial chemotherapy using miriplatin and cisplatin
in patients with advanced HCC. Patients first received a transarterial
chemotherapy with increasing doses of cisplatin through the hepatic artery
followed by a transarterial oily chemoembolization with miriplatin. Nine patients
were enrolled and no DLT was observed with any dose of cisplatin and miriplatin
suggesting that this combination can be safely administered. In some patients,
which all have received previous therapies, a disease stabilization was possible.
Overall, the results are clearly presented and the manuscript is well written.
Previous studies from Japan have already compared the efficacy of miriplatin
with cisplatin and observed a comparable short-term efficacy, but slightly better
tolerability for miriplatin. The study presented here indicates that both drugs can
also be safely administered together, which might lead to a better tumor control.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Phase I Study of Miriplatin combined with Transarterial Chemotherapy
using CDDP powder in Patients with Hepatocellular Carcinoma
Version: 1Date:17 June 2012
Reviewer: Arndt Vogel
Reviewer's report:
Kamimura performed a phase 1 study to determine the maximum tolerated dose
and dose-limiting toxicity for the combination of transarterial oily
chemoembolization and transarterial chemotherapy using miriplatin and cisplatin
in patients with advanced HCC. Patients first received a transarterial
chemotherapy with increasing doses of cisplatin through the hepatic artery
followed by a transarterial oily chemoembolization with miriplatin. Nine patients
were enrolled and no DLT was observed with any dose of cisplatin and miriplatin
suggesting that this combination can be safely administered. In some patients,
which all have received previous therapies, a disease stabilization was possible.
Overall, the results are clearly presented and the manuscript is well written.
Previous studies from Japan have already compared the efficacy of miriplatin
with cisplatin and observed a comparable short-term efficacy, but slightly better
tolerability for miriplatin. The study presented here indicates that both drugs can
also be safely administered together, which might lead to a better tumor control.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Phase I Study of Miriplatin combined with Transarterial Chemotherapy
using CDDP powder in Patients with Hepatocellular Carcinoma
Version: 1Date:17 June 2012
Reviewer: Arndt Vogel
Reviewer's report:
Kamimura performed a phase 1 study to determine the maximum tolerated dose
and dose-limiting toxicity for the combination of transarterial oily
chemoembolization and transarterial chemotherapy using miriplatin and cisplatin
in patients with advanced HCC. Patients first received a transarterial
chemotherapy with increasing doses of cisplatin through the hepatic artery
followed by a transarterial oily chemoembolization with miriplatin. Nine patients
were enrolled and no DLT was observed with any dose of cisplatin and miriplatin
suggesting that this combination can be safely administered. In some patients,
which all have received previous therapies, a disease stabilization was possible.
Overall, the results are clearly presented and the manuscript is well written.
Previous studies from Japan have already compared the efficacy of miriplatin
with cisplatin and observed a comparable short-term efficacy, but slightly better
tolerability for miriplatin. The study presented here indicates that both drugs can
also be safely administered together, which might lead to a better tumor control.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
assistant